Effect of risedronate on bone in renal transplant recipients

Maria Coco, James Pullman, Hillel W. Cohen, Sally Lee, Craig Shapiro, Clemencia Solorzano, Stuart Greenstein, Daniel Glicklich

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)1426-1437
Number of pages12
JournalJournal of the American Society of Nephrology
Issue number8
StatePublished - Aug 2012

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Effect of risedronate on bone in renal transplant recipients'. Together they form a unique fingerprint.

Cite this